Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma.

Casey DL, Wexler LH, Pitter KL, Samstein RM, Slotkin EK, Wolden SL.

Clin Cancer Res. 2019 Nov 7. doi: 10.1158/1078-0432.CCR-19-2631. [Epub ahead of print]


Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.

Slotkin EK, Diolaiti D, Shukla NN, Dela Cruz FS, Clark JJ, Gundem G, Yellapantula VD, Levine MF, You D, Ma P, Pachhal S, Ibanez Sanchez G, Benayed R, Jungbluth AA, Smyth LM, Mauguen A, Gushterova I, Ding H, Spraggon L, Darnell R, Califano A, Ladanyi M, Papaemmanuil E, Kung AL, Hyman DM, Roberts SS.

Cancer Discov. 2019 May;9(5):605-616. doi: 10.1158/2159-8290.CD-18-0953. Epub 2019 Mar 15.


Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions.

Ambati SR, Slotkin EK, Chow-Maneval E, Basu EM.

JCO Precis Oncol. 2018;2018. pii: Epub 2018 Sep 13. No abstract available.


A case report of concurrent embryonal rhabdomyosarcoma and diffuse large B-cell lymphoma in an adult without identifiable cancer predisposition.

Mathias MD, Ortiz MV, Magnan H, Ambati SR, Slotkin EK, Chou AJ, Walsh MF, Offit K, Moskowitz C, Kentsis A, Wexler LH.

Biomark Res. 2017 Feb 8;5:7. doi: 10.1186/s40364-017-0086-7. eCollection 2017.


Generation of conditional oncogenic chromosomal translocations using CRISPR-Cas9 genomic editing and homology-directed repair.

Spraggon L, Martelotto LG, Hmeljak J, Hitchman TD, Wang J, Wang L, Slotkin EK, Fan PD, Reis-Filho JS, Ladanyi M.

J Pathol. 2017 May;242(1):102-112. doi: 10.1002/path.4883. Epub 2017 Mar 30.


Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma.

Ortiz MV, Magnan H, Slotkin EK, Ambati SR, Chou AJ, Wexler LH, Meyers PA, Walsh MF, Heaton T, Girardi LN, Wolden SL, Price AP, Kennedy JA, Zehir A, Hameed M, Berger MF, Kentsis A, Shukla N.

J Pediatr Hematol Oncol. 2017 Nov;39(8):e443-e445. doi: 10.1097/MPH.0000000000000754.


Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas.

Shukla NN, Patel JA, Magnan H, Zehir A, You D, Tang J, Meng F, Samoila A, Slotkin EK, Ambati SR, Chou AJ, Wexler LH, Meyers PA, Peerschke EI, Viale A, Berger MF, Ladanyi M.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00028. Epub 2017 May 23.


A single-center experience with undifferentiated embryonal sarcoma of the liver.

Mathias MD, Ambati SR, Chou AJ, Slotkin EK, Wexler LH, Meyers PA, Magnan H.

Pediatr Blood Cancer. 2016 Dec;63(12):2246-2248. doi: 10.1002/pbc.26154. Epub 2016 Jul 18.


Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.

Ortiz MV, Kobos R, Walsh M, Slotkin EK, Roberts S, Berger MF, Hameed M, Solit D, Ladanyi M, Shukla N, Kentsis A.

Pediatr Blood Cancer. 2016 Aug;63(8):1368-74. doi: 10.1002/pbc.26002. Epub 2016 Apr 15.


MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.

Slotkin EK, Patwardhan PP, Vasudeva SD, de Stanchina E, Tap WD, Schwartz GK.

Mol Cancer Ther. 2015 Feb;14(2):395-406. doi: 10.1158/1535-7163.MCT-14-0711. Epub 2014 Dec 17.

Supplemental Content

Loading ...
Support Center